Market capitalization | $25.08b |
Enterprise Value | $37.72b |
P/E (TTM) P/E ratio | 19.75 |
EV/FCF (TTM) EV/FCF | 17.44 |
EV/Sales (TTM) EV/Sales | 2.43 |
P/S ratio (TTM) P/S ratio | 1.62 |
P/B ratio (TTM) P/B ratio | 4.22 |
Revenue growth (TTM) Revenue growth | 2.84% |
Revenue (TTM) Revenue | $15.50b |
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
27 Analysts have issued a IQVIA forecast:
27 Analysts have issued a IQVIA forecast:
Mar '25 |
+/-
%
|
||
Revenue | 15,496 15,496 |
3%
3%
|
|
Gross Profit | 4,264 4,264 |
3%
3%
|
|
EBITDA | 3,387 3,387 |
5%
5%
|
EBIT (Operating Income) EBIT | 2,272 2,272 |
9%
9%
|
Net Profit | 1,334 1,334 |
2%
2%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Provides biopharmaceutical development services and commercial outsourcing services
Head office | United States |
CEO | Ari Bousbib |
Employees | 88,000 |
Founded | 1950 |
Website | www.iqvia.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.